While updating the preemption chapter of his drug and device product liability treatise, Bexis came across a proposition he had not thought about in a long time. In two opinions in the Birmingham Hip (“BHR”) MDL, the court, under the aegis of Fed. R. Evid. 702, excluded expert testimony because it solely concerned a preempted... Continue Reading
